Journal
JOURNAL OF CLINICAL DENSITOMETRY
Volume 19, Issue 2, Pages 127-140Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jocd.2016.03.003
Keywords
Accreditation; certification; DXA; osteoporosis; quality
Categories
Funding
- Amgen
- Eli Lily
- Novartis
- GE
- Hologic
- Ache
- EMS
- Hypermarcas
- Medimaps
- Merck
- GE Healthcare
- MSD
- Roche
- Gamble
- Hospira
- Servier
- Pfizer
- Bristol Myers Squibb
- Abbvie
- PG
- Centocor
Ask authors/readers for more resources
Dual-energy X-ray absorptiometry (DXA) is a technology that is widely used to diagnose osteoporosis, assess fracture risk, and monitor changes in bone mineral density (BMD). The clinical utility of DXA is highly dependent on the quality of the scan acquisition, analysis, and interpretatidn. Clinicians are best equipped to manage patients when BMD measurements are correct and interpretation follows well-established standards. Poor-quality acquisition, analysis, or interpretation of DXA data may mislead referring clinicians, resulting in unnecessary diagnostic evaluations, failure to evaluate when needed, inappropriate treatment, or failure to provide medical treatment, with potentially ineffective, harmful, or costly consequences. Misallocation of limited healthcare resources and poor treatment decisions can be minimized, and patient care optimized, through meticulous attention to DXA instrument calibration, data acquisition and analysis, interpretation, and reporting. This document from the International Society for Clinical Densitometry describes quality standards for BMD testing at DXA facilities worldwide to provide guidance for DXA supervisors, technologists, interpreters, and clinicians. High-quality DXA testing is necessary for correct diagnostic classification and optimal fracture risk assessment, and is essential for BMD monitoring.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available